Merus Reports Dosing of First Patient in P-II Study Evaluating Petosemtamab in 3L+ mCRC
Shots:
- Merus reported the dosing of the first patient in its P-II study evaluating the safety and antitumor activity of petosemtamab monotx. in 3L+ metastatic colorectal cancer (mCRC) and as a post-anti-EGFR therapy
- The company is currently enrolling patients that lack mutations as detected in plasma by ctDNA NGS, including KRAS and NRAS in its P-II study
- Petosemtamab (MCLA-158) is a low-fucose IgG1 antibody that targets EGFR and LGR5. It acts through three mechanisms: inhibiting EGFR signaling, promoting EGFR internalization and degradation via LGR5 binding, and enhancing ADCC and ADCP activity
Ref: Merus | Image: Merus
Related News:- Merus Reports the US FDA’s Accelerated Approval of Bizengri (Zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NSCLC
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
An avid reader and a dedicated learner, Prince works as a Content Writer at PharmaShots. Prince possesses an exceptional quality of breaking down the barriers of words by simplifying the terms in digestible chunks to make content readable and comprehensible. Prince likes to read books and loves to spend his free time learning and upskilling himself.
